Previous 10 | Next 10 |
Gainers: Arbutus Biopharma (NASDAQ:ABUS) +47%. Ardelyx (NASDAQ:ARDX) +31%. Context Therapeutics (NASDAQ:CNTX) +19%. ImmunoGen (NASDAQ:IMGN) +17%. Skylight Health Group (NASDAQ:SLHG) +16%. Losers: BeyondSpring (NASDAQ:BYSI) -53%. Aditxt (NASDAQ:ADTX) -25%. CTI (NASDAQ:CTIC)...
Ardelyx, Inc. (NASDAQ: ARDX) has reported plans to launch IBSRELA, the approved treatment for irritable bowel syndrome with constipation (IBS-C) in adults in the second quarter of 2022. Mike Raab, president and chief executive officer of Ardelyx, stated, ȁ...
Ladenburg Thalmann has upgraded Ardelyx (ARDX +15.8%) to buy from neutral citing the company's novel irritable bowel syndrome ("IBS") with constipation drug Ibsrela (tenapanor). The firm has a $6 price target (~426% upside). Ardelyx is planning to launch the drug in Q2 2022. Analyst Matt...
Applied UV (NASDAQ:AUVI) +47%. Skylight Health Group (NASDAQ:SLHG) +27%. Ardelyx (NASDAQ:ARDX) +18%. IceCure Medical (NASDAQ:ICCM) +17%. Energy Focus (NASDAQ:EFOI) +17%. Ambarella (NASDAQ:AMBA) +15% on Q3 results VBI Vaccines (NASDAQ:VBIV) +14% wins FDA approval for Hepatitis B vacc...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! We’re starting off the day right with a look at the biggest pre-market stock movers for Wednesday! Source: oneinchpunch/Shutterstock.com News moving shares this morning include Omicron c...
Ardelyx (ARDX +28.8%) has recorded the biggest intraday gain in over two years on the back of its pre-market announcement of the launch of IBSRELA in Q2 2022 for irritable bowel syndrome with constipation (IBS-C) in adults. In reaction, Citi has lifted the price target for the biotech from $7...
Ardelyx (ARDX +1.3%) plans to launch its approved treatment for irritable bowel syndrome with constipation (IBS-C) in adults, IBSRELA ((tenapanor)) in Q2 of 2022. Mike Raab, president and CEO said, "By capturing even a modest share, in the mid to high single-digit of this large mark...
Ardelyx Launching IBSRELA® Second Quarter of 2022 - IBSRELA (tenapanor) the first and only NHE3 inhibitor approved for treatment of IBS-C in adults - IBSRELA potential peak net revenue greater than $500 million annually - Large and established IBS-C market in need o...
Ardelyx (NASDAQ:ARDX): Q3 GAAP EPS of -$0.42 misses by $0.09. Revenue of $1.18M (-56.5% Y/Y) misses by $0.02M. Press Release As of September 30, 2021, Ardelyx had total cash, cash equivalents and short-term investments of $141.7 million. For further details see: Ardelyx EPS misses by $0...
Ardelyx Reports Third Quarter 2021 Financial Results PR Newswire FREMONT, Calif. and WALTHAM, Mass. , Nov. 12, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of ...
News, Short Squeeze, Breakout and More Instantly...
Why The Stock Market Is Down Today Why is the stock market down today? The final week of June and the second quarter has been jam-packed with economic data and inflation-related events. Fed Chair Jerome Powell recently said that the global economy has entered a “new world”...
Ardelyx Announces $20 Million Financing Agreement with HealthCare Royalty Partners PR Newswire HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA ® in the United States in exchange for future hyperphosphatemia royalty payments from ...
Ardelyx Announces FDA Advisory Committee Meeting to Review XPHOZAH® NDA Tentatively Scheduled for November 16, 2022 PR Newswire WALTHAM, Mass. , June 21, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a missio...